Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
AstraZeneca
Merck Sharp & Dohme LLC
AstraZeneca
Seagen Inc.
Ferring Pharmaceuticals
Pfizer
Sichuan Baili Pharmaceutical Co., Ltd.
Merck Sharp & Dohme LLC
BeOne Medicines
Astellas Pharma Inc
Bayer
Eli Lilly and Company
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Novartis
Canadian Cancer Trials Group
Pfizer
Amgen
Bristol-Myers Squibb
National Cancer Institute (NCI)
AstraZeneca
AstraZeneca
AstraZeneca
ABX advanced biochemical compounds GmbH
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Aragon Pharmaceuticals, Inc.
Aragon Pharmaceuticals, Inc.
Aragon Pharmaceuticals, Inc.
Aragon Pharmaceuticals, Inc.
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Janssen Pharmaceutica N.V., Belgium
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
CSPC Megalith Biopharmaceutical Co.,Ltd.
Clarity Pharmaceuticals Ltd